Many retinal diseases, such as retinal detachment and diabetic retinopathy, are treated successfully by conventional laser irradiation. However, the benefit for the patient has to be considered carefully when macular irradiation is performed, because of the resultant laser scotoma that can lead to severe loss of visual acuity. Furthermore, the thermal destruction of photoreceptors does not contribute to the therapeutic effect in macular diseases that are caused by dysfunction of the RPE cells, such as drusen in early age-related macular degeneration (AMD), diabetic macular edema, and central serous retinopathy. Selectively destroying RPE cells while preserving the photoreceptors may be the appropriate treatment for these diseases.
5 The selective effect on RPE cells, that absorb approximately 50% of the incident green light,
6 due to their high melanosome content, was first demonstrated using 5-μs argon laser pulses at 514 nm, with a repetition rate of 500 Hz in experimental rabbit eyes.
5 Applying a train of brief, microsecond pulses that are on the order of the thermal relaxation time of the absorbing melanosomes (∼1 μs) leads to high peak temperature or, depending on the exposure duration, to the formation of microbubbles
7 8 9 10 11 12 13 around the melanosomes. Subsequently, the RPE cells are destroyed, whereas the background temperature increase remains at sublethal levels.
14 Thus, collateral thermal damage is avoided, and photoreceptors remain intact as shown in various studies. Histology at different time points after irradiation demonstrated restoration of the blood–retinal barrier by proliferating and migrating RPE cells within 14 days after treatment.
5 14 15 Clinical trials in which an Nd:YLF laser system was used with a pulse duration of 1.7 μs (up to 100 pulses, 100 and 500 Hz) demonstrated the clinical potential of this technique, confirming by microperimetry that central vision is not adversely affected after selective targeting (Roider J et al.
IOVS 1998;39:ARVO Abstract 104).
16